BioLineRx (BLRX) EBIT Margin (2024 - 2025)
BioLineRx (BLRX) recorded quarterly EBIT Margin of 1745.36% in Q4 2025, down 237.68% quarter-over-quarter from 516.86% in Q3 2025, and down 170769.0% on a YoY basis from N/an in Q4 2024.
BioLineRx (BLRX) EBIT Margin (2024 - 2025) Analysis & Trends
BioLineRx's EBIT Margin history runs 2 years deep, the most recent figure standing at 1745.36% for Q4 2025.
- In Q4 2025, EBIT Margin fell 170769.0% year-over-year to 1745.36%; the TTM figure through Dec 2025 stood at 871.78% (down 80126.0% YoY), while the FY2025 annual figure was 871.78%, down 80126.0% from the prior year.
- EBIT Margin was 1745.36% for Q4 2025 at BioLineRx, down from 516.86% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 37.67% in Q4 2024 to a low of 1745.36% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | -1,745.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,745.36% |
| Sep 30, 2025 | -516.86% |
| Jun 30, 2025 | -757.57% |
| Mar 31, 2025 | -937.65% |
| Dec 31, 2024 | -37.67% |
| Sep 30, 2024 | -108.98% |
| Jun 30, 2024 | -107.05% |
| Mar 31, 2024 | -70.34% |